☆ 4.7 Article

Global trajectory and future prospects of metronomic chemotherapy research: A scientometric analysis (2000-2022)

CANCER LETTERS (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Letter Virology

Bibliometric analysis of global research trends on monkeypox: Are we ready to face this challenge?

Kunming Cheng et al.

JOURNAL OF MEDICAL VIROLOGY (2023)

添加到收藏夹

Review Oncology

Metronomic Chemotherapy: Anti-Tumor Pathways and Combination with Immune Checkpoint Inhibitors

Elena Muraro et al.

Summary: Metronomic chemotherapy is an alternative approach for cancer treatment, which involves continuous administration of low-dose drugs to overcome drug resistance and toxic side effects. It can control tumor growth by inhibiting angiogenesis, suppressing tumor cell growth, and enhancing immune response. Combining metronomic chemotherapy with immune checkpoint inhibitors has shown synergistic therapeutic effects in preclinical and clinical studies. However, optimal drug combinations, sequence, and concentration-time factors still need to be evaluated in representative preclinical models.

CANCERS (2023)

添加到收藏夹

Review Pharmacology & Pharmacy

Nanoformulations-Based Metronomic Chemotherapy: Mechanism, Challenges, Recent Advances, and Future Perspectives

Vijay Kumar Panthi et al.

Summary: Cancer-related death is a global burden and conventional chemotherapy has limitations. Metronomic chemotherapy (MCT) is suggested as an alternative approach. Nanoformulations-based MCT has shown promising antitumor activity in preclinical and clinical settings. However, challenges and unanswered questions remain, and further research is necessary before implementing this treatment modality.

PHARMACEUTICS (2023)

添加到收藏夹

Article Oncology

Metronomic chemotherapy as a potential partner of immune checkpoint inhibitors for metastatic colorectal cancer treatment

Ji Hyung Hong et al.

Summary: The use of immune checkpoint inhibitors (ICIs) in clinical practice for the treatment of metastatic colorectal cancer (mCRC) is currently limited to a small subset of patients. Combining ICIs with anti-angiogenic inhibitors has shown promising efficacy in early phase trials. Additionally, low-dose metronomic (LDM) chemotherapy has potential as a combination partner with ICIs for immunologically cold mCRC tumors.

CANCER LETTERS (2023)

添加到收藏夹

Review Oncology

Chemotherapy: how to reduce its adverse effects while maintaining the potency?

Brianna et al.

Summary: Chemotherapy is a widely used anticancer treatment that targets rapidly dividing cells through various mechanisms. However, it often leads to unavoidable side effects such as hair loss, neuropathy, nausea and vomiting, cardiotoxicity, diarrhea, infertility, and chemo brain. While some of these side effects can be managed, others are unavoidable, limiting the effectiveness of chemotherapy in treating malignancy.

MEDICAL ONCOLOGY (2023)

添加到收藏夹

Article Computer Science, Information Systems

Analysis of direct citation, co-citation and bibliographic coupling in scientific topic identification

Rajmund Kleminski et al.

Summary: The study examines the impact of citation network structures on identifying valuable research topics in Computer Science literature. Extracting candidate phrases from abstracts and constructing citation networks, it finds that bibliographic coupling captures more unique information and combining it with other structures may add value. Combining direct citation and co-citation is questioned, with potential use in research topic identification method design.

JOURNAL OF INFORMATION SCIENCE (2022)

添加到收藏夹

Article Medicine, General & Internal

Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly and Frail Patients, with Diffuse Large B-Cell Lymphoma

Guido Bocci et al.

Summary: The upfront treatment of very elderly and frail patients with DLBCL is still controversial. This study reports the results of a metronomic all-oral DEVEC combined with i.v. rituximab in 22 elderly/frail DLBCL patients. The treatment showed promising clinical responses and the combination of metronomic VNR and ETO exhibited strong synergism against DLBCL cells. This low-dose schedule may be a favorable option for this subset of patients.

JOURNAL OF CLINICAL MEDICINE (2022)

添加到收藏夹

Review Medicine, General & Internal

Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows

Marina Elena Cazzaniga et al.

Summary: This review summarizes the advantages and challenges of metronomic chemotherapy (mCHT) in preclinical and clinical settings. In preclinical studies, mCHT has a significant effect on the tumor microenvironment, but the direct effects on tumor cells are less clear. Key issues that need to be addressed include the lack of definition of an optimal biological dose, administration method, and validation of predictive biomarkers. In the clinical context, low toxicity is the most recognized advantage of mCHT, but the type of study design, lack of randomized trials, and uncertainty in terms of doses and drugs are still challenges.

JOURNAL OF CLINICAL MEDICINE (2022)

添加到收藏夹

Article Oncology

Low-dose carboplatin reprograms tumor immune microenvironment through STING signaling pathway and synergizes with PD-1 inhibitors in lung cancer

Li Zhou et al.

Summary: The study demonstrated that low-dose carboplatin can transform cold tumors into hot tumors by activating the STING pathway, enhancing CD8(+) T-cell infiltration, and potentiate the anti-tumor effect of PD-1 inhibitors without adverse effects.

CANCER LETTERS (2021)

添加到收藏夹

Article Public, Environmental & Occupational Health

A Scientometric Analysis and Visualization of Research on Parkinson's Disease Associated With Pesticide Exposure

Chaoyang Liu et al.

FRONTIERS IN PUBLIC HEALTH (2020)

添加到收藏夹

Article Oncology

Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma

Xiran He et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Review Oncology

Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience

Cem Simsek et al.

JOURNAL OF ONCOLOGY (2019)

添加到收藏夹

Review Oncology

Current achievements and future perspectives of metronomic chemotherapy

Adriana Romiti et al.

INVESTIGATIONAL NEW DRUGS (2017)

添加到收藏夹

Review Biochemistry & Molecular Biology

A Combination of Immune Checkpoint Inhibition with Metronomic Chemotherapy as a Way of Targeting Therapy-Resistant Cancer Cells

Irina Kareva

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)

添加到收藏夹

Article Oncology

Radiotherapy prolongs the survival of advanced non-smallcell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev)

Pierpaolo Pastina et al.

ONCOTARGET (2017)

添加到收藏夹

Review Oncology

Metronomic chemotherapy: A relook at its basis and rationale

Tanujaa Rajasekaran et al.

CANCER LETTERS (2017)

添加到收藏夹

Review Oncology

Metronomic chemotherapy: An attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance

Irina Kareva et al.

CANCER LETTERS (2015)

添加到收藏夹

Review Oncology

Metronomic chemotherapy from rationale to clinical studies: A dream or reality?

Antonio Gnoni et al.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)

添加到收藏夹

Review Medicine, Research & Experimental

A systematic literature analysis of correlative studies in low-dose metronomic chemotherapy trials

Gemma Cramarossa et al.

BIOMARKERS IN MEDICINE (2014)

添加到收藏夹

Review Oncology

Metronomics: towards personalized chemotherapy?

Nicolas Andre et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2014)

添加到收藏夹

Article Oncology

Metronomics as maintenance treatment in oncology: time for chemo-switch

Prabhat Singh Malik et al.

FRONTIERS IN ONCOLOGY (2014)

添加到收藏夹

Review Oncology

Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy

Mariana S. Nars et al.

INTERNATIONAL JOURNAL OF CANCER (2013)

添加到收藏夹

Article Oncology

Low-Dose Metronomic Oral Administration of Vinorelbine in the First-line Treatment of Elderly Patients With Metastatic Breast Cancer

Raffaele Addeo et al.

CLINICAL BREAST CANCER (2010)

添加到收藏夹

Article Computer Science, Information Systems

The Structure and Dynamics of Cocitation Clusters: A Multiple-Perspective Cocitation Analysis

Chaomei Chen et al.

JOURNAL OF THE AMERICAN SOCIETY FOR INFORMATION SCIENCE AND TECHNOLOGY (2010)

添加到收藏夹

Review Oncology

Metronomic chemotherapy: new rationale for new directions

Eddy Pasquier et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2010)

添加到收藏夹

Article Oncology

Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast Cancer

Silvia Dellapasqua et al.

JOURNAL OF CLINICAL ONCOLOGY (2008)

添加到收藏夹

Review Medicine, General & Internal

Molecular origins of cancer: Tumor angiogenesis

Robert S. Kerbel

NEW ENGLAND JOURNAL OF MEDICINE (2008)

添加到收藏夹

Article Oncology

Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

Francois Ghiringhelli et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)

添加到收藏夹

Article Hematology

Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity

Y Shaked et al.

BLOOD (2005)

添加到收藏夹

Review Oncology

The anti-angiogenic basis of metronomic chemotherapy

RS Kerbel et al.

NATURE REVIEWS CANCER (2004)

添加到收藏夹

Review Oncology

Metronomic scheduling: the future of chemotherapy?

G Gasparini

LANCET ONCOLOGY (2001)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.